The Rosalind Franklin Institute’s Strategic Progress in Purposeful Innovation
Paul Matthews, Director of The Rosalind Franklin Institute, reflects on a year of strategic renewal and progress. The institute has refreshed its science strategy to balance blue-skies discovery with translational outcomes, focusing specifically on creating tools to transform twenty-first-century drug discovery. This bottom-up approach fostered a culture of 'team science' and diversified leadership. Key achievements include strengthened partnerships with UK universities and local entities like the Mary Lyon Centre and Diamond Light Source. Notably, a revolutionary lens-free X-ray microscope is being developed with the University of Southampton. The institute also prioritizes industry collaboration to advance chemistry and precompetitive discovery, while leveraging convening power to support government scientific advisors. These efforts aim to address economic and healthcare challenges by delivering tangible benefits to the UK population, backed by recent government commitment to science funding.
Wire timeline
The Rosalind Franklin Institute’s Strategic Progress in Purposeful Innovation
Paul Matthews, Director of The Rosalind Franklin Institute, reflects on a year of strategic renewal and progress. The institute has refreshed its science strategy to balance blue-skies discovery with translational outcomes, focusing specifically on creating tools to transform twenty-first-century drug discovery. This bottom-up approach fostered a culture of 'team science' and diversified leadership. Key achievements include strengthened partnerships with UK universities and local entities like the Mary Lyon Centre and Diamond Light Source. Notably, a revolutionary lens-free X-ray microscope is being developed with the University of Southampton. The institute also prioritizes industry collaboration to advance chemistry and precompetitive discovery, while leveraging convening power to support government scientific advisors. These efforts aim to address economic and healthcare challenges by delivering tangible benefits to the UK population, backed by recent government commitment to science funding.
UKRI